Does Wellcare Cover Prolia?
The verdict
Covered on most plans
Wellcare (Centene) covers Prolia for its predominantly Medicare and Medicaid members, most often under the Medicare Part B medical benefit as a q6-month clinic injection billed under HCPCS J0897. As of September 1, 2025, the interchangeable Jubbonti biosimilar is replacing Prolia on Medicare plans. Medicaid covers Prolia for osteoporosis with high fracture risk per state preferred drug list at nominal cost-share. Dual-eligible members (Medicare + Medicaid) often pay $0, as Medicaid covers the 20% Part B coinsurance that Medicare does not. The Amgen copay support card is not available to Medicare or Medicaid beneficiaries under federal anti-kickback rules.
Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Wellcare using your member ID.
Key facts
Wellcare dual-eligible members (Medicare + Medicaid) often pay $0 for Prolia: Medicare covers 80% under Part B and Medicaid typically covers the 20% coinsurance — but the Amgen copay card is federally prohibited for any Medicare or Medicaid enrollee.
CMS Medicare-Medicaid dual-eligible cost-sharing rules; federal anti-kickback statute
Prolia is most often a Medicare Part B buy-and-bill drug billed under HCPCS J0897 — not a Part D pharmacy pickup. The $2,100 Part D OOP cap does not apply to the Part B pathway.
CMS Local Coverage Determination L33394; Medicare.gov
Wellcare is a Centene company with state-specific Medicaid PDLs — Prolia coverage under Medicaid varies by state. Verify on your state Wellcare Medicaid drug list.
Centene/Wellcare state Medicaid managed-care plans, wellcare.com
Medicare vs. commercial coverage
Whether Wellcare covers Prolia depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.
Medicare
Part D & Advantage plans
Medicare Part B (medical benefit — operative pathway for most Wellcare Medicare members): Prolia is covered as a clinician-administered subcutaneous injection every 6 months, billed under HCPCS J0897 incident to a physician service per LCD L33394. Original Medicare covers 80% after the Part B deductible; the member pays 20% coinsurance, approximately $357 per injection at average pricing. As of September 1, 2025, the interchangeable Jubbonti biosimilar (denosumab-bddz) is replacing Prolia on Medicare plans — Wellcare's Medicare plans follow the broader industry transition. Wellcare Medicare Advantage plans may require prior authorization with documentation of osteoporosis and high fracture risk; step therapy toward Jubbonti may apply. The $2,100 Part D out-of-pocket cap does NOT apply to Part B drugs — this is critical for members who might compare Prolia's cost to Part D specialty drugs. For dual-eligible members, Medicaid typically covers the 20% Part B coinsurance, resulting in $0 out-of-pocket.
Commercial / Employer
Group & marketplace plans
Commercial/Employer: Wellcare's commercial footprint is minimal — it is primarily a Medicare Part D and Medicaid managed-care organization. Where a Wellcare commercial plan exists, Prolia is covered under the medical benefit with prior authorization per plan policy. ACA/Individual: limited; medical-benefit coverage where offered. Medicaid: Wellcare/Centene Medicaid managed-care plans cover Prolia for osteoporosis with high fracture risk per state preferred drug list, with prior authorization at nominal cost-share ($0–$4). Because Wellcare is a Centene federation of state Medicaid PDLs, PDL coverage varies by state — verify on your state Wellcare Medicaid drug list. Not covered outside FDA-approved osteoporosis and bone-loss indications on any Wellcare line of business.
The 3 boxes you must tick to get approved
Commercial plans that will consider Prolia require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.
Meet all 3 and you have a documented case for approval. Missing any one is the most common reason requests are denied.
Your cost, three ways
What Prolia actually costs you swings enormously depending on how it's covered. Here's the realistic range.
Paying cash
~$1,786–$2,507 per 60 mg dose without insurance (estimates: Medicare.org ~$1,786; GoodRx ~$2,507). Actual cash price varies by site of care.
List price with no coverage — before any manufacturer savings card.
With coverage
Medicare Part B with Medicaid dual coverage: Medicare pays 80% after the Part B deductible; Medicaid typically covers the remaining 20% coinsurance for dual-eligible members — out-of-pocket cost is often $0. Medicare-only Wellcare members (without Medicaid): 20% coinsurance after the Part B deductible, approximately $357 per injection at average pricing. Wellcare Medicare Advantage: observed copays on Medicare plans range $0–$500 per injection depending on plan design — verify on your specific plan. Medicaid only: nominal $0–$4 cost-share per state PDL.
Typical monthly copay once prior authorization is approved.
Bridge program
Amgen offers copay support for Prolia for commercially insured patients. This program is NOT available to Medicare or Medicaid beneficiaries — federal anti-kickback rules prohibit manufacturer copay assistance for government program enrollees. Most Wellcare members are on Medicare or Medicaid and cannot use Amgen's copay card.
Reduced copay through the assistance program, where eligible.
All figures are estimates. The Part D $2,100 out-of-pocket cap does NOT apply to the Part B medical pathway. Verify your specific cost-share on your Wellcare member portal or by calling member services.
Check YOUR exact coverage in 3 steps
General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.
- 1
Find your Wellcare state plan drug list and check denosumab coverage
Wellcare is a Centene federation — coverage specifics vary by state. Go to wellcare.com and navigate to your state plan's drug formulary or preferred drug list for Medicaid members, or your Medicare Part D formulary. Search for 'denosumab,' 'Prolia,' or 'Jubbonti.' Because Wellcare's Medicare plans have transitioned to Jubbonti as of September 1, 2025, confirm whether Prolia or Jubbonti is the covered product on your specific plan.
- 2
Ask your clinician about dual-eligible cost-sharing and the Jubbonti transition
If you are dual-eligible (enrolled in both Medicare and Medicaid), your prescribing clinician can confirm how the cost-sharing works: Medicare Part B covers 80% and Medicaid typically covers the 20% coinsurance, resulting in $0 out-of-pocket. Also confirm which product — Prolia or Jubbonti biosimilar — your current Wellcare Medicare plan covers, as the transition to Jubbonti began September 1, 2025.
- 3
Verify that you are not relying on the Amgen copay card — it does not apply to you
Federal anti-kickback rules prohibit Medicare and Medicaid beneficiaries from using manufacturer copay assistance programs, including Amgen's Prolia copay support card. If you are a Wellcare Medicare or Medicaid member, you cannot use this program. The operative cost-relief for dual-eligible members is Medicaid covering the Part B 20% coinsurance — confirm this applies to your state's Wellcare Medicaid plan by calling member services.
Options if Wellcare won't cover Prolia
A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.
Jubbonti (denosumab-bddz)
The interchangeable biosimilar replacing Prolia on Wellcare Medicare plans as of September 1, 2025. Same denosumab molecule, same 60 mg dose, same q6-month clinic injection. Existing Prolia authorizations should carry over automatically; confirm with your prescriber.
Fosamax (alendronate) — generic bisphosphonate
Oral generic bisphosphonate, covered at low/Tier 1 cost-share on most Medicaid and Medicare formularies. Common first-line osteoporosis treatment, particularly for Medicaid members where access to injectable biologics may involve additional steps.
Reclast (zoledronic acid)
Annual IV bisphosphonate infusion administered in a clinic and billed under the medical benefit. Typically covered at lower cost-share than Prolia on Medicaid and Medicare plans. Covered for patients unable to tolerate oral bisphosphonates.
These options are listed for information only — your own clinician decides what is appropriate for you.
❓Frequently Asked Questions
Yes. Wellcare covers Prolia under the Medicare Part B medical benefit as a clinician-administered injection every 6 months, billed under HCPCS J0897. As of September 1, 2025, Wellcare's Medicare plans are transitioning to the Jubbonti interchangeable biosimilar (same denosumab molecule). Prior authorization with documentation of osteoporosis and high fracture risk is typically required. The $2,100 Part D cap does not apply to Part B drugs.
Dual-eligible Wellcare members are often the best positioned for Prolia cost. Medicare Part B covers 80% of the approved cost after the Part B deductible; your Wellcare Medicaid plan typically covers the remaining 20% coinsurance, resulting in $0 out-of-pocket. Confirm that your specific state's Wellcare Medicaid plan includes this cost-share coverage by calling Wellcare member services or reviewing your plan documents.
No. Federal anti-kickback rules prohibit Medicare and Medicaid beneficiaries from using manufacturer copay assistance programs, including Amgen's Prolia copay support. Most Wellcare members are enrolled in Medicare, Medicaid, or both and cannot use this card. This is a federal rule, not a Wellcare-specific restriction. Dual-eligible members already have Medicaid covering the 20% Part B coinsurance, which typically results in $0 cost — no manufacturer card is needed.
Yes, particularly for Medicaid. Wellcare operates Medicaid managed-care plans as a Centene company across multiple states, and each state has its own preferred drug list. PA criteria, tier placement, and cost-share for Prolia under Medicaid can differ by state. Always verify on your specific state Wellcare Medicaid drug list. Wellcare's Medicare plans follow a more uniform national policy, including the September 2025 transition to Jubbonti biosimilar.
No. For most Wellcare Medicare members, Prolia and Jubbonti are Part B medical-benefit drugs billed in the clinic under HCPCS J0897 — not Part D pharmacy drugs. The $2,100 Part D out-of-pocket cap (2026) applies to Part D drugs only. Part B cost-sharing for Wellcare Medicare members is the 20% coinsurance after the Part B deductible — often covered by Medicaid for dual-eligibles.
Related Articles
Does Aetna Cover Vyvanse? 2026 CVS Caremark Formulary
Aetna covers Vyvanse via CVS Caremark — generic lisdexamfetamine preferred, brand non-preferred. 70 mg/day QL per Policy 5.60.024; age-22 PA required.
Read moreDoes Aetna Cover Prolia? CVS Caremark Medical Benefit | Curex
Aetna covers Prolia under the medical benefit with PA — a q6-month clinic injection, not Part D. Jubbonti biosimilar now preferred on CVS Caremark.
Read moreDoes Anthem Cover Adderall? 2026 Coverage Guide | Curex
Anthem covers Adderall through CarelonRx — generic preferred, brand non-preferred. Step therapy may apply on some plans. Verify your Anthem plan.
Read moreDoes Anthem Cover Contrave? 2026 Brand Coverage Guide | Curex
Anthem covers Contrave only if your plan has a weight-loss benefit. Many plans carve it out. CurAccess ~$99/mo is often the fastest path.
Read moreDoes Aetna Cover Contrave? 2026 CVS Caremark Guide | Curex
Aetna (CVS Caremark) often excludes Contrave under AOM carve-outs. Where covered, CVS BMI prior auth applies. Medicare bars it by law. CurAccess ~$99/mo.
Read moreDoes Aetna Cover Forteo? 2026 Coverage Guide
Aetna (CVS) often excludes brand Forteo in favor of generic teriparatide or Bonsity. Teriparatide is covered with PA and bisphosphonate step therapy. 2026.
Read moreThis content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Wellcare before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation.